Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Achievement of MRD negativity identified as prognostic factors for PFS and OS in primary plasma cell leukemia (PCL), while the ability to get ASCT was linked to OS; median OS and PFS were 33.5 and 15.4 months for the cohort (N=70).”
Title: Prognostic Implications of Measurable Residual Disease and Autologous Hematopoietic Stem Cell Transplantation in Primary Plasma Cell Leukemia in the Era of Novel Agents
Authors: Qiling Bu, Yiwen Jiang, Jingjing Deng, Ping Wang, Zhiyao Zhang, Guangzhong Yang, Ying Tian, Wen Gao, Aijun Liu, Yun Leng, Yin Wu, Wenming Chen, and Hong-Hu Zhu
You can read the Full Article in Transplantation and Cellular Therapy.
You can find more posts featuring Robert Orlowski on OncoDaily.
